Acadia Pharmaceuticals (ACAD) PT Lowered to $34 at Needham & Company Following Nuplazid Schizophrenia Miss

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/3/2026

1. AAPL
2. PLTR
3. CRWD
4. VRTX
5. CHKP
6. ON
7. HNGE
8. INSP
9. AXSM
10. RXRX

Go back to Acadia Pharmaceuticals (ACAD) PT Lowered to $34 at Needham & Company Following Nuplazid Schizophrenia Miss

Acadia Pharma (ACAD) Phase 3 ENHANCE Trial of Pimavanserin Did Not Achieve Primary Endpoint

July 22, 2019 4:09 PM EDT

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) announced top-line results from its Phase 3 ENHANCE study, which evaluated pimavanserin as an adjunctive treatment in adult schizophrenia patients with persistent inadequate response to their current antipsychotic therapy. A total of 396 patients with moderate-to-severe psychotic symptoms were randomized to receive either pimavanserin or placebo added to their current antipsychotic treatment. There is currently no FDA-approved adjunctive treatment for schizophrenia patients with inadequate response to existing therapies.

In the study, adding pimavanserin to existing antipsychotic treatment showed a consistent trend in improvement of psychotic symptoms, however the results... More